 Multiple Sclerosis
"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 3 | 2 | 5 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 2 | 3 | | 2000 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 6 | 2 | 8 | | 2011 | 3 | 2 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 4 | 0 | 4 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 3 | 0 | 3 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2020 | 4 | 1 | 5 | | 2021 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Zanotto T, Lynch SG, Hausdorff JM, Sosnoff JJ. Frailty in multiple sclerosis: A closer look at the deficit accumulation framework. Mult Scler. 2022 05; 28(6):1000-1001.
-
Mazzà C, Alcock L, Aminian K, Becker C, Bertuletti S, Bonci T, Brown P, Brozgol M, Buckley E, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, Chynkiamis N, Ciravegna F, Del Din S, Eskofier B, Evers J, Garcia Aymerich J, Gazit E, Hansen C, Hausdorff JM, Helbostad JL, Hiden H, Hume E, Paraschiv-Ionescu A, Ireson N, Keogh A, Kirk C, Kluge F, Koch S, Küderle A, Lanfranchi V, Maetzler W, Micó-Amigo ME, Mueller A, Neatrour I, Niessen M, Palmerini L, Pluimgraaff L, Reggi L, Salis F, Schwickert L, Scott K, Sharrack B, Sillen H, Singleton D, Soltani A, Taraldsen K, Ullrich M, Van Gelder L, Vereijken B, Vogiatzis I, Warmerdam E, Yarnall A, Rochester L. Technical validation of real-world monitoring of gait: a multicentric observational study. BMJ Open. 2021 12 02; 11(12):e050785.
-
Zanotto T, Galperin I, Mirelman A, Yehezkiyahu S, Estes J, Chen L, Regev K, Karni A, Schmitz-Hübsch T, Paul F, Lynch SG, Akinwuntan AE, Devos H, Hausdorff JM, Sosnoff JJ. Frailty and Falls in People Living With Multiple Sclerosis. Arch Phys Med Rehabil. 2022 05; 103(5):952-957.
-
Qian Y, Arellano G, Ifergan I, Lin J, Snowden C, Kim T, Thomas JJ, Law C, Guan T, Balabanov RD, Kaech SM, Miller SD, Choi J. ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Rep. 2021 08 24; 36(8):109602.
-
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
-
Wijburg MT, Warnke C, McGuigan C, Koralnik IJ, Barkhof F, Killestein J, Wattjes MP. Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. J Neurol Neurosurg Psychiatry. 2021 02; 92(2):177-188.
-
Hsieh KL, Mirelman A, Shema-Shiratzky S, Galperin I, Regev K, Shen S, Schmitz-Hübsch T, Karni A, Paul F, Devos H, Sosnoff JJ, Hausdorff JM. A multi-modal virtual reality treadmill intervention for enhancing mobility and cognitive function in people with multiple sclerosis: Protocol for a randomized controlled trial. Contemp Clin Trials. 2020 10; 97:106122.
-
Mondal S, Kundu M, Jana M, Roy A, Rangasamy SB, Modi KK, Wallace J, Albalawi YA, Balabanov R, Pahan K. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rß1 internalization and suppress EAE. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21557-21567.
-
Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
-
Shema-Shiratzky S, Hillel I, Mirelman A, Regev K, Hsieh KL, Karni A, Devos H, Sosnoff JJ, Hausdorff JM. A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity. J Neurol. 2020 Jul; 267(7):1912-1921.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|